Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

Apple's growth these days is a bit modest, as revenue for the last three months of 2024 was up just 4%, but it still has opportunities in its services business to drive more growth. That segment ...

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.